SCHEMBL7206532

SCHEMBL7206532

COc1ccc2c(C(C)=O)csc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
HPGD P15428 3/20 0.51
MAPK1 P28482 2/20 0.51
CYP3A4 P08684 2/20 0.51
MTNR1A P48039 2/20 0.46
MTNR1B P49286 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HTT P42858 2/20 0.46
PRNP P04156 1/20 0.46
TSHR P16473 1/20 0.46
PPARG P37231 1/20 0.46
MAPK10 P53779 1/20 0.46
NCOA2 Q15596 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
MAPT P10636 5/20 0.44
KDM4E B2RXH2 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8555827 0.87 MTNR1A (0.56) ALDH1A1HPGDMAPK1CYP3A4MTNR1A
SCHEMBL2814704 0.87 CA12 (0.49) ALDH1A1HPGDMAPK1MTNR1AMTNR1B
SCHEMBL2811677 0.86 KDM4E (0.49) ALDH1A1HPGDMAPK1MTNR1AMTNR1B
SCHEMBL2813714 0.82 NPSR1 (0.45) ALDH1A1HPGDMAPK1CYP3A4MTNR1A
SCHEMBL7208283 0.81 CLK1 (0.52) ALDH1A1HPGDMAPK1MTNR1AMTNR1B
SCHEMBL1324265 0.81 ALDH1A1 (0.50) ALDH1A1HPGDCYP3A4NPSR1HTT
SCHEMBL10983397 0.79 MAPT (0.42) ALDH1A1HPGDMAPK1CYP3A4MTNR1A
SCHEMBL7208275 0.79 KDM4E (0.48) ALDH1A1HPGDMTNR1AMTNR1BNPSR1
SCHEMBL10982579 0.78 NPSR1 (0.41) ALDH1A1HPGDMAPK1MTNR1AMTNR1B
SCHEMBL497770 0.77 CYP2A6 (0.44) ALDH1A1CYP3A4HTTTSHRRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1274706-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2003-01-15 EP disclosed
US-6462069-B2 KINASE INHIBITORS; ANTICANCER AGENTS AGOURON PHARMACEUTICALS, INC. 2002-10-08 US disclosed
WO-2001079198-A9 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMA (US) 2002-05-16 WO disclosed
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases LIGHPOINTE COMMUNICATION, INC. 2002-01-17 US disclosed
WO-2001079198-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMACEUTICALS, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases CDK3, CCNK, CDK1 ALDH1A1 3414/4885HPGD 1189/4885MAPK1 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.